Skip to main content
. 2000 Dec;44(12):3408–3413. doi: 10.1128/aac.44.12.3408-3413.2000

TABLE 5.

Adverse events reported in ≥2% of patients in the ITT population

Adverse event No. (%) of patients in treatment group
Linezolid (n = 400) Oxacillin-dicloxacillin (n = 419)
Nausea 23 (5.8) 24 (5.7)
Headache 22 (5.5) 16 (3.8)
Vomiting 13 (3.3) 8 (1.9)
Hypertension 12 (3.0) 1 (0.2)
Diarrhea 11 (2.8) 12 (2.9)
Localized pain 11 (2.8) 3 (0.7)
Dyspepsia 10 (2.5) 7 (1.7)
Insomnia 10 (2.5) 9 (2.1)
Dizziness 9 (2.3) 3 (0.7)
Abdominal pain (localized) 8 (2.0) 5 (1.2)
Constipation 7 (1.8) 13 (3.1)
Pruritus (nonapplication site) 6 (1.5) 9 (2.1)
Fever 5 (1.3) 11 (2.6)
HHS Vulnerability Disclosure